News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1โ€“36
Matches
161
Sources here
2
Companies here
1
Search results Stored financial headlines

Active search

161 matching headlines

Ticker or company: M1RN34Main companies and provider mentions
Clear
Latest

finance.yahoo.com Regulatory and legal

Why Are Moderna (MRNA) Shares Soaring Today

Why Are Moderna (MRNA) Shares Soaring Today What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7.1% in the afternoon session after the company presented at the Morgan Stanley Global Healthcare Conference and generated positive sentiment around its vaccine pipeline. During the conference presentation, investor attention centered on key clinical and regulatory developments across Moderna's pipeline, per TipRanks. โ€ฆ

Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil
Read at finance.yahoo.com
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
Just inNext headlines
seekingalpha.com Earnings Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Moderna continues volatile trading with 9% gain

[Moderna To Request Emergency Authorization For Its Vaccine After Positive Trial Results] Maddie Meyer/Getty Images News Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) climbed almost 9% on Thursday, closing at $158.07 after gaining $12.45 from the previous close. This came as the mRNA-medicine company continued its volatile trading โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Balance sheet Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Moderna: Another Day, Another Big Stock Move. Is the Cancer Vaccine Rally Back On?

Moderna President Stephen Hoge says the company remains on track for its longtime goal of reaching cash breakeven by 2028. Continue Reading

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Earnings Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher

Quick Read Moderna surged 5% to $152.83, extending a stunning 137% one-month run fueled solely by its Phase 2b melanoma vaccine data showing a 49% reduction in recurrence risk. BioNTech edged up just 1% despite running a rival mRNA cancer vaccine program, signaling markets โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

This Dividend Stock Is Beating the Market in 2026 and Yields 2.36%

Dividends stamp by Olivier Le Moal via iStock Merck (MRK) was at the center of a major cancer-treatment update in August. Specifically, the drugmaker and Moderna (MRNA) said their personalized mRNA cancer therapy, intismeran autogene, delivered positive results in a Phase 3 study involving โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Macro sensitivity Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?

Shares of Moderna MRNA have staged a remarkable comeback this year as investors increasingly warm to the possibility that the company can rebuild its business beyond COVID-19 vaccines. After becoming one of the biggest pandemic winners, Moderna struggled with sharply lower COVID-19 vaccine demand, โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Moderna (MRNA) Ascends While Market Falls: Some Facts to Note

Moderna (MRNA) closed at $146.69 in the latest trading session, marking a +1.89% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.48%. At the same time, the Dow lost 0.29%, and the tech-heavy Nasdaq lost โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Regulatory and legal Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Moderna's COVID Vaccine Was a Historic Success. Could Its Cancer Vaccine Be Even Bigger?

Moderna (NASDAQ: MRNA) has skyrocketed by more than 460% over the past 12 months as the company has made outstanding clinical and regulatory progress. Notably, Moderna earned approval for mFLUSIVA, an influenza vaccine that beat some competing vaccines in phase 3 studies. This new โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Analyst action Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know

Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know What Happened? A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Analyst action Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat

Quick Read Moderna surges 8% while cancer-vaccine partner Merck slips 0.3% and peer BioNTech gains just 0.5%, pointing to a Moderna-specific momentum or short-squeeze event. XBI falls 0.1% and SPY rises less than 1%, eliminating both sector tailwinds and broad market strength as drivers โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.)

Moderna (NASDAQ: MRNA) is famous for developing vaccines using mRNA technology (thus, its ticker symbol) -- including its highly popular COVID-19 vaccine a few years ago. Enthusiasm over that vaccine helped propel the stock some 434% in 2020 and another 143% in 2021. Wow, โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
seekingalpha.com Earnings Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks

[Health Care Medical Concept] ogichobanov/iStock via Getty Images The healthcare sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 4.91% in August, outperforming the broader S&P 500 (SPY [https://seekingalpha.com/symbol/SPY]), which advanced 2.68% during the month. Healthcare stocks benefited from strength in biotechnology and medical technology, while healthcare services, managed โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

What Does Moderna (MRNA) Bird Flu Phase 3 Trial Mean For Its Growth?

Moderna (NasdaqGS:MRNA) has started a Phase 3 trial of its mRNA based bird flu vaccine, moving the program into late stage testing. The trial is supported by a major international partnership focused on pandemic preparedness. Moderna has tied the program to commitments for equitable โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Is Moderna (MRNA) Fully Valued After Its New 2032 Convertible Notes?

Moderna (MRNA) drew fresh attention after completing a US$2.6b zero coupon convertible notes offering due 2032 and separately announcing an additional US$2b 2032 convertible notes issue, both placed under Rule 144A. Moderna's recent completion of zero coupon notes and the additional 2032 convertible announcement โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Balance sheet Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Moderna (MRNA) Stock Looks Expensive On Sales After A Very Large Run

Moderna stock has delivered a very large 1 year gain, yet the company still screens as expensive on broad valuation checks. After that kind of move, the question for investors is whether the current price already reflects much of the good news around the โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?

Moderna (NASDAQ: MRNA) has been one of the better-performing large-cap biotechs this year. The company's shares are up 404% to date and have soared 515% over the trailing-12-month period (as of writing). The company's shares are changing hands for about $148 apiece. Notice that's โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Analyst action Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Why Moderna (MRNA) Stock Is Down Today

Why Moderna (MRNA) Stock Is Down Today What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 2.9% in the afternoon session after Rothschild & Co Redburn analyst Simon Baker downgraded the company to Sell from Neutral on valuation concerns. Baker raised Moderna's price target โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Regulatory and legal Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?

Moderna MRNA recently secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine. The decision is a significant milestone for the company, which gets an opportunity to establish a foothold in another multibillion-dollar market while further diversifying its revenue base beyond COVID-19 vaccines. โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Analyst action Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Modernaโ€™s Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 45% Stock Drop

Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target. Continue Reading

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

This Fund Bought Moderna Before It Nearly Tripled. See Its 2 New Stock Picks

Bamco, the advisory arm of Ron Baron's Baron Capital Group, opened a new position in Moderna (NASDAQ:MRNA) during the second quarter of 2026. The fund bought about 2 million shares of the firm in the June quarter. The timing worked out. In August, Moderna โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Biotech Is Popping. No One Seems to Care.

Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors. If a sector rallies in a forest and no one's there to hear it, does it really cash in? Moderna turned investors' heads a โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Down More Than 30% From Its Peak, Is Now the Perfect Time to Buy Sandisk Stock?

Sandisk (NASDAQ: SNDK) has been the best-performing stock in the S&P 500 this year, rising by around 550%. That's well above second-place Moderna, which has risen by around 420%. With a stellar performance like that, some investors may be surprised to learn that Sandisk โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Moderna to Present at Upcoming Conferences in September 2026

CAMBRIDGE, MA / ACCESS Newswire / September 1, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Morgan Stanley 24th Annual Global Healthcare Conference, on Monday, September 14 at 10:00 a.m. ET Bernstein Insights: Healthcare Leaders and Disruptors โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Regulatory and legal Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Moderna (MRNA) Soars 156% in August โ€” Hereโ€™s What Propelled The Rally

Moderna Inc. (NASDAQ:MRNA) saw its share price soar by 156 percent in Augustโ€”making it the highest-gaining stock for the monthโ€”driven primarily by the strong clinical trial results of its therapy candidate for melanoma, supported by a recent regulatory approval for its updated COVID-19 vaccines. โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

There Was No Beating Moderna in August. These Are the Best and Worst S&P 500 Stocks for the Month.

Moderna stock surged 158% in August to lead the S&P 500, while Edison International plunged 27% to rank last in the index. Continue Reading

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Moderna Led the S&P 500 in August as Edison International Sank

Moderna stock surged 158% in August to lead the S&P 500, while Edison International plunged 27% to rank last in the index. Continue Reading

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Analyst action Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Jim Cramer Called Moderna Inc. (NASDAQ:MRNA) & Merckโ€™s Trial Results Encouraging

August has been a great month for the shares of Merck & Co., Inc. (NYSE:MRK) and Moderna Inc. (NASDAQ:MRNA), to say the least. The former's stock closed 12.6% higher and the latter's stock closed 176% higher on August 19th. The stocks surged after a โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

What Do Moderna (MRNA) FDA Vaccine Approvals Mean For Its Respiratory Push?

Moderna (NasdaqGS:MRNA) received FDA approval for updated Spikevax and mNEXSPIKE COVID-19 vaccines tailored to the latest SARS-CoV-2 subvariant. The FDA also cleared mFlusiva, Moderna's first mRNA based influenza vaccine for adults aged 50 and over. These approvals expand Moderna's respiratory vaccine portfolio and mark โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

โ€˜This Breakup Saved You Far More Than Moderna Ever Couldโ€™: Orman to Woman Dumped After 180% Spike

Quick Read MRNA surged 177% on August 19 but fell 27% the next session and 14% from its surge close within a week, validating the caller's sale. Orman's 5% rule caps speculative single-stock exposure to $100,000 on a $2 million portfolio, separating survivable speculation โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Regulatory and legal Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Moderna (MRNA) Plans $2B of Zero-Coupon Convertible Debt. Is the Capped Call Enough to Control Dilution?

Moderna, Inc. (NASDAQ:MRNA) proposed a private placement of $2.0 billion in convertible senior notes due in 2032, with an option for initial purchasers to acquire another $300 million. The notes would be senior unsecured obligations, carry no regular interest, and have no principal accretion. โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Jim Cramer Says Hold on to Moderna (MRNA) After Phase 3 Cancer Trial

On the August 26 episode of Mad Money, a caller mentioned that they had purchased 1,000 shares of Moderna, Inc. (NASDAQ:MRNA) at $54 a couple of weeks prior, watched the price go up to $150, and asked what they should do. Jim Cramer replied: โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
seekingalpha.com Market update Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Arcturus, Moderna fall after BioNTech's cancer vaccine setback

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio Messenger RNA drug developers Arcturus Therapeutics (ARCT [https://seekingalpha.com/symbol/ARCT]) and Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) traded lower on Friday after BioNTech (BNTX [https://seekingalpha.com/symbol/BNTX]) decided to halt a mid-stage trial โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Q2 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Moderna (NASDAQ:MRNA) and its peers. Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Moderna (MRNA) & Merck (MRK): Whatโ€™s Happening With These Two Stocks?

On August 19, 2026, Moderna, Inc. (NASDAQ:MRNA) and Merck & Co., Inc. (NYSE:MRK) said that their personalized mRNA cancer vaccine, combined with Merck's Keytruda, met its main goals in a first-ever Phase 3 trial for melanoma. The news sent Moderna shares up as much โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Moderna (MRNA), Merck (MRK) Cancer Vaccine Wins in Late-Stage Trial

On August 19, 2026, Moderna, Inc. (NASDAQ:MRNA) and Merck & Co., Inc. (NYSE:MRK) said their personalized melanoma vaccine, intismeran, combined with Merck's Keytruda, met its goals in a Phase 3 trial of 1,137 patients. It reduced the risk of cancer recurrence and spread compared โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026
finance.yahoo.com Balance sheet Main company ๐Ÿ‡ง๐Ÿ‡ท Brazil

Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes

Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debt Moderna has also purchased a hedge overlay intended to offset dilution up to a cap initially equal to โ€ฆ

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +520.4% M1RN34 stored weekly price path from 26 Sep 2025 to 18 Sep 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context